Study on Sputnik Light (first component of Sputnik V) vaccine's efficacy among the elderly in Argentina published in EClinicalMedicine journal
Retrieved on:
Monday, September 13, 2021
MOSCOW, Sept. 13, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces publication of a study in EClinicalMedicine (an open access peer-reviewed clinical journal published by The Lancet, one of the world's most respected medical journals) on efficacy of Russian Sputnik Light coronavirus vaccine (the first component of Sputnik V vaccine) among the elderly in the Province of Buenos Aires (Argentina).
Key Points:
- The study is available at:
Sputnik Light is the first component of Sputnik V based on human adenovirus serotype 26. - Sputnik Light has also demonstrated efficacy against hospitalizations at 82.1-87.6%.
- Key advantages of Sputnik Light:
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V the world's first registered vaccine against coronavirus. - Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.